Tag: IP newsletter

The Supreme Court’s decision to hear AstraZeneca’s appeal and this month’s NAFTA hearings on an Eli Lilly complaint shine a ...

While there was certainly a win on the costs of genetic testing, the long-term effects of Transgenomic’s departure from the ...

It has become fashionable to declare the Trans-Pacific Partnership intellectual property provisions a disaster for innovation in Canada, writes Richard ...